Viral infectivity of albumin and plasma protein fraction

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Original research, reviews, anti case reports discussing viral infectivity of blood- and plasma-derived products were reviewed to determine the potential viral infectivity of human serum albumin (HSA) and plasma protein fraction (PPF). Data concerning vital infectivity, vital screening anti inactivation procedures, and viral outbreaks associated with blood and plasma products were extracted and evaluated for pertinence to HSA and PPF. The starting material used for fractionation, the manufacturing process, postmanufacturing handling, and immunocompetence of HSA or PPF recipients were assessed to determine risk of symptomatic viral disease after transfusion. Both HSA and PPF are manufactured with pasteurization procedures that have led to an excellent viral safety record based on 50 years of clinical use. One outbreak of hepatitis B was associated with PPF as a result of an unreliable manufacturing process that has been corrected. The pasteurization process is effective in eradicating known viral pathogens when good manufacturing practices are followed. Continued surveillance of such products is warranted for viruses not included in routine screening procedures and for those that are resistant to current inactivation methods.

Original languageEnglish (US)
Pages (from-to)996-1001
Number of pages6
JournalPharmacotherapy
Volume16
Issue number6 I
StatePublished - Nov 1996

Fingerprint

Albumins
Serum Albumin
Blood Proteins
Pasteurization
Disease Outbreaks
Virus Inactivation
Immunocompetence
Virus Diseases
Hepatitis B
plasma protein fraction
Viruses
Safety
human ALB protein
Research

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Viral infectivity of albumin and plasma protein fraction. / Erstad, Brian L.

In: Pharmacotherapy, Vol. 16, No. 6 I, 11.1996, p. 996-1001.

Research output: Contribution to journalArticle

@article{e31e9457d3254f12a8d53236ac7b0cb1,
title = "Viral infectivity of albumin and plasma protein fraction",
abstract = "Original research, reviews, anti case reports discussing viral infectivity of blood- and plasma-derived products were reviewed to determine the potential viral infectivity of human serum albumin (HSA) and plasma protein fraction (PPF). Data concerning vital infectivity, vital screening anti inactivation procedures, and viral outbreaks associated with blood and plasma products were extracted and evaluated for pertinence to HSA and PPF. The starting material used for fractionation, the manufacturing process, postmanufacturing handling, and immunocompetence of HSA or PPF recipients were assessed to determine risk of symptomatic viral disease after transfusion. Both HSA and PPF are manufactured with pasteurization procedures that have led to an excellent viral safety record based on 50 years of clinical use. One outbreak of hepatitis B was associated with PPF as a result of an unreliable manufacturing process that has been corrected. The pasteurization process is effective in eradicating known viral pathogens when good manufacturing practices are followed. Continued surveillance of such products is warranted for viruses not included in routine screening procedures and for those that are resistant to current inactivation methods.",
author = "Erstad, {Brian L}",
year = "1996",
month = "11",
language = "English (US)",
volume = "16",
pages = "996--1001",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "6 I",

}

TY - JOUR

T1 - Viral infectivity of albumin and plasma protein fraction

AU - Erstad, Brian L

PY - 1996/11

Y1 - 1996/11

N2 - Original research, reviews, anti case reports discussing viral infectivity of blood- and plasma-derived products were reviewed to determine the potential viral infectivity of human serum albumin (HSA) and plasma protein fraction (PPF). Data concerning vital infectivity, vital screening anti inactivation procedures, and viral outbreaks associated with blood and plasma products were extracted and evaluated for pertinence to HSA and PPF. The starting material used for fractionation, the manufacturing process, postmanufacturing handling, and immunocompetence of HSA or PPF recipients were assessed to determine risk of symptomatic viral disease after transfusion. Both HSA and PPF are manufactured with pasteurization procedures that have led to an excellent viral safety record based on 50 years of clinical use. One outbreak of hepatitis B was associated with PPF as a result of an unreliable manufacturing process that has been corrected. The pasteurization process is effective in eradicating known viral pathogens when good manufacturing practices are followed. Continued surveillance of such products is warranted for viruses not included in routine screening procedures and for those that are resistant to current inactivation methods.

AB - Original research, reviews, anti case reports discussing viral infectivity of blood- and plasma-derived products were reviewed to determine the potential viral infectivity of human serum albumin (HSA) and plasma protein fraction (PPF). Data concerning vital infectivity, vital screening anti inactivation procedures, and viral outbreaks associated with blood and plasma products were extracted and evaluated for pertinence to HSA and PPF. The starting material used for fractionation, the manufacturing process, postmanufacturing handling, and immunocompetence of HSA or PPF recipients were assessed to determine risk of symptomatic viral disease after transfusion. Both HSA and PPF are manufactured with pasteurization procedures that have led to an excellent viral safety record based on 50 years of clinical use. One outbreak of hepatitis B was associated with PPF as a result of an unreliable manufacturing process that has been corrected. The pasteurization process is effective in eradicating known viral pathogens when good manufacturing practices are followed. Continued surveillance of such products is warranted for viruses not included in routine screening procedures and for those that are resistant to current inactivation methods.

UR - http://www.scopus.com/inward/record.url?scp=0029850665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029850665&partnerID=8YFLogxK

M3 - Article

C2 - 8947970

AN - SCOPUS:0029850665

VL - 16

SP - 996

EP - 1001

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 6 I

ER -